Opinion|Videos|January 2, 2025
ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL
Panelists discuss how long-term SEQUOIA trial data presented at ASH 2024 inform the selection between covalent BTK inhibitors zanubrutinib and acalabrutinib in treatment-naive CLL, including considerations for combining these agents with obinutuzumab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- SEQUOIA researchers presented their 5-year follow-up data at this year’s ASH 2024 — could you share key updates from their abstract as well as your impressions? Do these data influence your decision when selecting among the covalent BTKi in treatment-naive CLL?
- How do you decide between acala vs zanu? In which patients would you consider adding obinutuzumab?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5